Korro Bio, Inc. (KRRO) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Korro Bio, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines based on RNA editing technology. The company operates as a single reportable segment focused on discovering, developing, and commercializing therapies for rare and prevalent diseases. As of November 10, 2025, the company had 9,417,295 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Collaboration Revenue | $1,090 | $0 | $5,100 | $0 |
| Total Operating Expenses | $20,327 | $23,292 | $76,559 | $68,870 |
| Net Loss | $(18,061) | $(20,999) | $(67,218) | $(62,382) |
| Net Loss Per Share (Basic/Diluted) | $(1.92) | $(2.26) | $(7.16) | $(7.11) |
| Cash, Cash Equivalents & Marketable Securities | $102,479 | N/A | N/A | N/A |
| Accumulated Deficit | $(333,804) | N/A | N/A | N/A |
Note: Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $102.5 million ($24.2M cash + $68.3M short-term securities + $10.0M long-term securities).
Material Changes vs. Prior Period
- Revenue: The company recognized $1.1 million in collaboration revenue for Q3 2025 and $5.1 million for the nine months ended September 30, 2025, derived from its research collaboration with Novo Nordisk. No collaboration revenue was recognized in the comparable 2024 periods.
- Operating Expenses: Total operating expenses decreased by $2.97 million in Q3 2025 compared to Q3 2024, driven by reductions in external research and development costs. However, for the nine-month period, expenses increased by $7.69 million, primarily due to increased personnel costs prior to workforce reductions and higher clinical trial expenses for the KRRO-110 program.
- Liquidity: Cash and cash equivalents decreased from $55.6 million at year-end 2024 to $24.2 million at September 30, 2025. Total cash, cash equivalents, and marketable securities declined from $164.0 million to $102.5 million over the same period.
- Restructuring: The company initiated a workforce reduction of 19% (21 positions) in May 2025, incurring $1.2 million in severance costs. A subsequent restructuring was announced in November 2025 (see below).
Guidance, Outlook, and Material Events
- Clinical Trial Pivot (KRRO-110): The Phase 1/2a REWRITE clinical trial for KRRO-110 (AATD) did not reach projected levels of functional protein in patients. The company is pivoting to a GalNAc delivery system for AATD and expects to nominate a development candidate in 2026. No additional single ascending dose (SAD) patient cohorts are planned for KRRO-110.
- New Candidate (KRRO-121): The company nominated KRRO-121, a GalNAc-conjugated oligonucleotide targeting urea cycle disorders (UCD) and hepatic encephalopathy (HE). A regulatory filing for a first-in-human trial is planned for the second half of 2026.
- Novo Nordisk Collaboration Pause: Effective November 11, 2025, the company and Novo Nordisk agreed to a 12-month pause on their research collaboration. During this hold period, R&D activities and payment obligations are suspended. The company does not expect to recognize material collaboration revenue during this period.
- November 2025 Restructuring: On November 12, 2025, the company implemented a strategic restructuring to extend its cash runway, including a workforce reduction of approximately 34%. The company estimates one-time restructuring charges of approximately $2.4 million, with the majority expected to be recognized in Q4 2025.
- Cash Runway: Management expects existing cash, cash equivalents, and marketable securities ($102.5 million) to fund operations into the second half of 2027, subject to the impact of the recent restructuring and collaboration pause.
Investor Verification Checklist
- Cash Burn Rate: Verify the impact of the November 2025 workforce reduction and the Novo Nordisk collaboration pause on the projected cash runway into late 2027.
- Novo Nordisk Agreement: Review the terms of the 12-month pause to confirm the suspension of revenue recognition and the specific wind-down cost reimbursement arrangements.
- KRRO-110 Data: Assess the implications of the failure to reach projected protein levels on the timeline for the GalNAc delivery pivot and the potential for further delays in the AATD program.
- Restructuring Costs: Monitor Q4 2025 financials for the recognition of the estimated $2.4 million in restructuring charges associated with the November workforce reduction.
- Capital Needs: Evaluate the company's ability to raise additional capital if the cash runway shortens due to the paused collaboration or extended development timelines for the GalNAc platform.